OM336 in Seropositive Autoimmune Diseases
Key facts
- Phase
- Phase 1
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07229144, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Lakefront Biotherapeutics West LLC
- Trial code
- NCT07229144EU 2025-524100-29-00
- Record updated
- 15 June 2026
- Original description
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.Read full original descriptionShow less
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Inclusion: Diagnosis of active seropositive autoimmune disease; Relapsed/refractory after ≥2 prior/ongoing treatments; Body weight ≥ 50 kg; Willing to comply with and study requirements and procedures.
Exclusion: Previous treatment with a BCMA-targeted therapy; Major surgery within 3 months of screening or planned during the study; Clinically significant infection within 3 months of screening; Pregnant or breastfeeding.